Windtree Therapeutics Inc (WINT)

[surf1944]

7:50AM Discovery Labs: New pharmacoeconomic analysis shows lower rate of reintubation observed with SURFAXIN treatment may reduce hospital costs associated with bronchopulmonary dysplasia (DSCO) 2.24 : Co announced the release of data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with SURFAXIN may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia (BPD) when compared with reintubation rates of infants treated with the current global market leading surfactants, Curosurf and Survanta.